- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT01495780
eRT Remote Health Monitoring
Feasibility and Cost Effectiveness of Physiological Monitoring at Home in COPD Patients
Remote Health Monitoring (RHM) is the assessment of one's own symptoms at home between doctor visits, using things like at-home breathing tests, electronic diaries to answer questionnaires, and other monitoring devices. The hypothesis of this study is that the health and quality of life of people with COPD who do RHM for one year will be better than people with COPD who do not do RHM. Subjects who are at least 40 years old, have been diagnosed with chronic obstructive pulmonary disease (COPD), also known as chronic bronchitis or emphysema, and are current or former smokers will be invited to participate. This study is paid for by eResearch Technology (eRT).
Subjects will complete 2 visits at UCLA, separated by one year of RHM. All subjects will participate in RHM. RHM will involve daily monitoring at home using a few electronic devices: blood oxygen levels, symptoms, medication use, breathing tests, and activity monitoring. Visits will include physical exam and medical history, ECG, questionnaires, breathing tests, and exercise tests.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Tipo di studio
Iscrizione (Effettivo)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
California
-
Los Angeles, California, Stati Uniti, 90095
- UCLA David Geffen School of Medicine
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Age >40 years.
- Clinical diagnosis of moderate to severe COPD in accordance with the definition of the American Thoracic Society (ATS).9
- Smoking history >10 pack-years.
- Postbronchodilator FEV1/FVC<70% and FEV1<70% based on NHANES III reference values
- Domestic situation felt to be supportive of remote health monitoring.
- Ability to give informed consent.
Exclusion Criteria:
- Clinical diagnosis of asthma.
- Pulmonary disease other than COPD (e.g., lung cancer, sarcoidosis, active tuberculosis, bronchiectasis, pulmonary fibrosis, cystic fibrosis, or alpha-1-antitrypsin deficiency) or had lung volume reduction.
- Any other active disease that, in the opinion of the investigator, would put the safety of the subject at risk through study participation (e.g. unstable cardiovascular disease, renal failure, stroke).
- Previously diagnosed cancer is considered a significant disease unless it is in complete remission for 2 years at the initial visit.
- Any other disease that is life-threatening and carries a prognosis less than two years that, in the opinion of the investigator, is likely to influence the clinical course during the conduct of this trial.
- Myocardial infarction within 6 weeks of enrolment.
- Use of long-term oxygen therapy (LTOT) prescribed for greater than 12 hours a day.
- A known or suspected history of drug or alcohol abuse within 2 years prior to the initial visit.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Prevenzione
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Remote Health Monitoring
Subjects assigned to this arm will conduct daily at-home health monitoring using several electronic devices that will transmit data back to the study team.
Everyday, subjects will measure pulse oximetry (SpO2) using a finger clip, answer questions about symptoms and medication use, answer a quality of life questionnaire, perform breathing tests, and record physical activity (using a physical activity monitor that will be mailed to the study team).
Wearing the activity monitor is optional and will only occur during months 1, 6, and 12.
|
1 year of remote health monitoring of symptoms, medication use, breathing tests, physical activity, and healthcare utilization.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Compliance with daily RHM
Lasso di tempo: 1 year
|
Compliance with daily RHM as a percentage of study days
|
1 year
|
|
Integrity of spirometric data
Lasso di tempo: 1 year
|
Integrity of the spirometric data in terms of the standard American Thoracic Society and European Respiratory Society criteria for acceptability and repeatability.
|
1 year
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Numero di visite mediche
Lasso di tempo: 1 anno
|
1 anno
|
|
|
Rate of adoption of RHM
Lasso di tempo: 1 year
|
Time it takes for subjects to become compliant with daily RHM
|
1 year
|
|
Treatment adherence
Lasso di tempo: 1 year
|
Treatment adherence in terms of percentage of days prescribed treatment* is taken (* treatment separate from study, prescribed by personal physician)
|
1 year
|
|
Time to first COPD exacerbation
Lasso di tempo: 1 year
|
Time to first COPD exacerbation as defined by standard criteria.
|
1 year
|
|
Number of COPD exacerbations per year
Lasso di tempo: 1 year
|
1 year
|
|
|
Proportion of subjects experiencing one or more exacerbations
Lasso di tempo: 1 year
|
1 year
|
|
|
Mean daily FEV1
Lasso di tempo: 1 year
|
1 year
|
|
|
Mean daily IC
Lasso di tempo: 1 year
|
1 year
|
|
|
Mean daily activity level
Lasso di tempo: 1 year
|
1 year
|
|
|
Mean daily SpO2
Lasso di tempo: 1 year
|
1 year
|
|
|
Daily symptom scores
Lasso di tempo: 1 year
|
1 year
|
|
|
Number of emergency department visits
Lasso di tempo: 1 year
|
1 year
|
|
|
Number of hospitalizations
Lasso di tempo: 1 year
|
1 year
|
|
|
Number of days spent in hospital
Lasso di tempo: 1 year
|
1 year
|
|
|
Health care costs
Lasso di tempo: 1 year
|
Inferred health care costs using a standard cost framework model
|
1 year
|
Collaboratori e investigatori
Collaboratori
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- eRT RHM
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Remote Health Monitoring
-
Philips Clinical & Medical Affairs GlobalReclutamentoChirurgia non cardiaca | Unità di terapia intensiva (UTI)Stati Uniti, Germania
-
The Hong Kong Polytechnic UniversityCompletatoDispositivo inefficaceHong Kong
-
Philips Clinical & Medical Affairs GlobalReclutamentoTerapia intensiva | Catetere dell'Arteria Polmonare (PAC) | Catetere di Swan-GanzStati Uniti, Germania
-
Rhaeos, Inc.Reclutamento
-
Médipôle Lyon-VilleurbanneCompletatoArresto cardiaco | Insufficienza cardiaca acuta (AHF)Francia
-
Johns Hopkins UniversitySchool of Biomedical Sciences, University of Otago, Dunedin, New Zealand; Dig...CompletatoDisturbo da stress post-traumaticoStati Uniti
-
Universitaire Ziekenhuizen KU LeuvenTerminato
-
McGill University Health Centre/Research Institute...Canadian Institutes of Health Research (CIHR); Greybox Solutions Inc.Completato
-
Biotronik SE & Co. KGCompletatoFibrillazione ventricolare | Tachicardia ventricolare | Insufficienza cardiaca congestiziaDanimarca, Germania, Israele, Australia, Austria, Repubblica Ceca, Lettonia
-
St Elizabeth HealthcareCompletatoSospetta aritmiaStati Uniti